PO (156124) and febuxostat (FEB) (SML1285) were purchased from Sigma–Aldrich (St. Louis, MO, USA). The primary antibodies used in the present study were purchased from Bioworld Technology (Nanjing, China) and were as follows: rabbit anti-collagen 3A1, rabbit anti-α-SMA, rabbit anti-fibronectin, rabbit anti-vimentin, rabbit anti-E-cadherin, rabbit anti-NLRP3, rabbit anti-ASC, rabbit anti-caspase-1, rabbit anti-IL-1β, rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and rabbit anti-TGFβ1 (BS7028,
BS70000, BS90514,
BS1491,
BS1098, BS90948, BS6205, BS5641,
AP0063, BS72410,BS91338). The assay kits for UA (
ab65344), creatinine (
ab65340), xanthine oxidase (XOD) (
ab102522), IL-1β (
ab197742), and IL-18 (
ab216165) were purchased from Abcam (Cambridge, UK). The
PrimeScript™ RT Master mix was obtained from Takara (Takara, Japan) and the
FastStart Universal SYBR Green master mix was obtained from Roche (Basel, Switzerland).
Shui G., Cai Z., Wang F., Chen T., Huang X., Cai Y, & Mi X. (2022). Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation. BMC Complementary Medicine and Therapies, 22, 278.